publicações selecionadas
-
artigo académico
- High B7-H3 protein expression in Medulloblastoma is associated with metastasis and unfavorable patient outcomes. Diagnostic Pathology. 2025
- Randomized experimental population-based study to evaluate the acceptance and completion of and preferences for cervical cancer screening 2024
- Correction: Alves et al. WNK2 Inhibits Autophagic Flux in Human Glioblastoma Cell Line. Cells 2020, 9, 485. Cells. 2024
- Glucose Metabolism as a Potential Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia. Pharmaceutics. 2024
- The Usefulness of an Online Simplified Screening Questionnaire (SSQ) in Identifying Work-Related Cancers. Healthcare. 2023
- MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma. Cancers. 2021
- Modulating chitosan-PLGA nanoparticle properties to design a co-delivery platform for glioblastoma therapy intended for nose-to-brain route. Drug Delivery and Translational Research. 2020
- A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis. Molecular Oncology. 2020
- A 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasms—Granting a Positive Outcome. Cancers. 2020
- WNK2 Inhibits Autophagic Flux in Human Glioblastoma Cell Line. Cells. 2020
- Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients. Molecular Biology Reports. 2020
- A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems. Drug Delivery and Translational Research. 2020
- Coronarin D Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Glioblastoma Cell Line. Biomolecules. 2019
- Modified ingenol semi-synthetic derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines. Investigational New Drugs. 2019
- Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling. Cells. 2019
- Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer 2018
- Monocarboxylate transporter 1 is a key player in glioma-endothelial cell crosstalk. Molecular Carcinogenesis. 2017
- Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells. Oncotarget. 2017
- Immunosensor for Pancreatic Cancer Based on Electrospun Nanofibers Coated with Carbon Nanotubes or Gold Nanoparticles. ACS Omega. 2017
- Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics. 2017
- AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors. Oncotarget. 2017
- Racial/Ethnic Disparities in Cervical Cancer Screening and Outcomes. Acta Cytologica. 2016
- Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Research. 2016
- Transcriptional profiling of HOXA9-regulated genes in human glioblastoma cell models. Genomics Data. 2015
- AXL as a modulator of sunitinib response in glioblastoma cell lines. Experimental Cell Research. 2015
- Silencing of the tumor suppressor gene WNK2 is associated with upregulation of MMP2 and JNK in gliomas. Oncotarget. 2015
- In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma. Nanoscale. 2015
- Silencing of WNK2 is associated with upregulation of MMP2 and JNK in gliomas. Oncotarget. 2015
- Low RKIP expression associates with poor prognosis in bladder cancer patients. Virchows Archiv. 2013
- In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas.. Translational Oncology. 2013
- Zeolite Structures Loading with an Anticancer Compound As Drug Delivery Systems. Journal of Physical Chemistry C. 2012
- Angiogenic Potential of Gellan-Gum-Based Hydrogels for Application in Nucleus Pulposus Regeneration: In Vivo Study. International Review of Neurobiology. 2012
- Encapsulation of a-cyano-4-hydroxycinnamic acid into a NaY zeolite. Carbohydrate Polymers. 2011
- Loss of RKIP expression during the carcinogenic evolution of endometrial cancer. Journal of Clinical Pathology. 2011
- Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World Journal of Clinical Oncology. 2011
- Loss of RKIP expression is associated with poor survival in GISTs. Virchows Archiv. 2009
- Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology. 2009
- Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer. 2009
- Liquid-Based Cytology in DNA-Based Molecular Research Viability and Potential Application. Analytical and Quantitative Cytology and Histology. 2009
- KIT activation in uterine cervix adenosquamous carcinomas by KIT / SCF autocrine/paracrine stimulation loops. Gynecologic Oncology. 2008
- Genetic Profile of Gliosarcomas. American Journal of Pathology. 2000
-
artigo de conferência
-
capítulo de livro
- Chapter 20 - Implications of RKIP protein in cancer prognosis and therapy response: A literature update 2020
- Implications of RKIP protein in cancer prognosis and therapy response: A literature update 2020
- Bevacizumab for Glioblastoma Treatment: Reviewing Biological and Clinical Hypothesis for its Success and Failures 2016
- Brain Tumor Metabolism — Unraveling Its Role in Finding New Therapeutic Targets 2015
- Pediatric High-Grade Glioma: Role of Microsatellite Instability 2012
- Malignant Gliomas: Role of Platelet-Derived Growth Factor Receptor A (PDGFRA) 2011
-
documento
- SPINT2 Expression in Cancer: Focus on Its Role and Therapeutic Impact in BRAF-Mutated Melanoma 2025
- Treatment with 3-bromopyruvate boosts the effect of chemotherapy in acute myeloid leukemia 2025
- SPINT2 reduces melanoma aggressiveness and improves therapeutic response 2024
- An in silico approach to identify Brachyury target genes in prostate cancer 2022
- An in silico approach to prostate cancer biomarkers 2022
- Embryonic T-box transcription factor Brachyury in androgen-dependent prostate cancer models 2022
- SPINT2 downregulation increases melanoma aggressiveness features 2022
- The implication of RKIP loss in primary resistance to EGFR inhibitors in NSCLC: a novel predictive biomarker? 2022
- SPINT2: a potential biomarker for melanoma patients 2021
- Untangling the role of RKIP in NSCLC aggressiveness: an in vitro /in vivo and in silico analysis 2021
- Exploring the predictive andtherapeutic value of the embryonic T-box transcription factor Brachyury inlung cancer 2021
- Exploring the predictive and therapeutic value of the embryonic T-box transcription factor Brachyury in lung cancer 2021
- A proteína RKIP como um novo preditor de resposta a terapias anti-EGFR em cancro do pulmão 2021
- Compreender a regulação e sinalização da RKIP no cancro do colo do útero: RKIP/HER loop 2021
- Embryonic T-box transcription factor Brachyury as a predictive biomarker and therapeutic target in lung cancer 2021
- Fator de transcrição embrionário T-box Brachyury como biomarcador de resposta e alvo terapêutico em cancro do pulmão 2021
- RKIP protein as a novel predictor of EGFR targeted therapies in lung cancer 2021
- Embryonic T-box transcription factor Brachyury as a predictive biomarker andtherapeutic target in lung cancer 2021
- Therapeutic relevance of SPINT2 in Melanoma. 2019
- RKIP protein as a potential prognostic, aggressiveness and therapy response biomarker in HNSCC 2019
- RKIP protein as a novel predictor of EGFR targeted therapies in lung cancer 2019
- RKIP protein induces HER receptors activation and positively modulate its pharmacological targeting in cervical cancer 2019
- Abstract P15: SPINT2 as a therapeutic biomarker in Melanoma 2019
- RKIP protein as a novel predictor of EGFR targeted therapies in lung cancer 2018
- RKIP protein induces HER receptors activation and positively modulate its pharmacological targeting in cervical cancer 2018
- RKIP protein induces HER receptors activation and positively modulate its pharmacological targeting in cervical cancer. 2018
- Study of functional role and therapeutic influence of the tumor suppressor gene SPINT2 in Melanoma. 2018
- The biological role of RKIP in head and neck cancer: an in vivo and in vitro study 2018
- RKIP protein as a novel predictor of EGFR targeted therapies in Lung Cancer. 2018
- Study of functional role and therapeutic influence of the tumor suppressor gene SPINT2 in Melanoma 2018
- Loss of SPINT2 is frequent in gliomas, leading to increases glioma cell growth and invasion, via a MMP2 activity 2018
- Understanding the cellular metabolic reprogramming associated with bevacizumab therapy in glioblastoma 2017
- Role of AKT pathway in the predictive response of Allitinib, a new generation EGFR-inhibitor, in a panel of HNSCC cell lines. 2015
- Monocarboxylate Transporter 1 (MCT1) expression at hypoxic conditions in glioblastomas: functional role and regulation 2015
- STUDY OF TERT AND MECHANISTICALLY RELATED MOLECULES IN MEDULLOBLASTOMAS 2014
- WNT6 promoter methylation associates with its expression in glioblastoma 2014
- STUDY OF TERT AND MECHANISTICALLY RELATED MOLECULES INMEDULLOBLASTOMAS 2014
- The semi-synthetic ingenol C derived from Euphorbia tirucalli induces cell death via autophagy but not apoptosis in human glioma cancer cells. 2013
- Profile of genomic alterations of gliomas 2013
- Association of SMAD7 single nucleotide polymorphisms with risk and prognosis of colorectal cancer in a Portuguese population 2013
- Association of ESR1 Polymorphisms with Tamoxifen Response in Women with Estrogen Receptor-Positive Breast Cancer 2013
- Testing a Novel Irreversible Anti-EGFR Drug for Head and Neck Cancer Treatment. 2013
- Relevance of HES1 expression in human gliomas: molecular and clinical correlates 2013
- Epigenetic inactivation of SPINT2 in High Grade Gliomas 2013
- Study of microsatellite instability (MSI) and mutations of MSI-target genes in large cohort of Brazilian colorectal cancer patients 2013
- Biallelic mutations in MMR gene in a retrospective series of CNS tumors 2013
- SPINT2 hypermethylation - a common event in high-grade gliomas 2013
- RKIP downregulation associates with poor prognosis in bladder cancer patients 2013
- Molecular study and inhibition of MET receptor in paediatric high-grade glioma 2012
- Molecular determinants of efficacy of met receptor inhibition in paediatric glioblastoma. 2012
- Study of msi phenotype and novel target genes associated with msi phenotype in medulloblastomas 2012
- RKIP downregulation associates with poor prognosis in bladder cancer patients 2012
- MET receptor tyrosine kinase overexpression in paediatric malignant gliomas and in vitro response to tyrosine kinase inhibitor 2011
- Novel genetic Instability in Paediatric High Grade Glioma 2011
- Associations between functional EGFR -216G/T, -191C/A, and Intron 1 (CA)n Repeat polymorphisms and glioma risk 2010
- EGFRvIII deletion mutations in paediatric high grade glioma and response to targeted therapy in paediatric glioma cell lines 2009
- Microsatellite instability: A new type of genetic instability in medulloblastomas? 2009
- Analysis of MAP kinase signalling pathway in KIT & PDGFRA wild-type GISTs. 2008
- Differential mechanisms of Temozolomide resistance in paediatric glioma cell lines 2008
- Absence of KIT gene mutations and amplification in medulloblastomas. 2008
- Analysis of the mitotic checkpoint competence in glioblastoma cell lines. 2008
- Molecular characterization of KIT gene in cervix adenosquamous carcinomas. 2007
- Liquid based cytology in molecular research: viability and potential applications. 2007
- Genomic and transcriptomic profile of glioblastomas with KIT gene amplification. 2007
- Study of KIT Oncogene in Medulloblastomas 2007
- Evaluation of mitotic checkpoint integrity in glioblastoma cell lines. 2006
- Analysis of TP53 mutations in Diffuse Astrocytomas. 2006
- Association of EGFR Intron 1 CA Repeat with Glioma Risk 2006
- No Association between EGFR Promoter Gene Polymorphisms and Gliomas Risk 2006
- No Association between EGFR Promoter Gene Polymorphisms and Gliomas Risk. 2006